Capsid Modified Bluetongue Virus 16 (BTV16) as a Virulytic Oncotherapy Agent

Capsid Modified Bluetongue Virus 16 (BTV16) as a Virulytic Oncotherapy Agent

Authors Information

1 Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, IR Iran
2 Razi Vaccine and Serum Research Institute, Karaj, IR Iran

Article Notes and Dates

Biotechnology and Health Sciences: May 2017, S(1); e45667.Published Online: March 9, 2017
Article Type: Research Article; Received: January 13, 2017; Revised: January 26, 2017; Accepted: January 28, 2017
DOI: http://dx.doi.org/10.5812/bhs.45667
To Cite : Naserpour Farivar T, Najafipour R, Alizadeh S A, Azimi S M, Johari P. et al. Capsid Modified Bluetongue Virus 16 (BTV16) as a Virulytic Oncotherapy Agent, Biotech Health Sci. 2017 ;S(1):e45667. doi: 10.5812/bhs.45667.
Copyright: Copyright © 2017, Biotechnology and Health Sciences. .
Abstract
1. Background
2. Objectives
3. Methods
4. Results and Discussion
Acknowledgements
Footnotes
References
  • 1. Li JK. Oncolytic bluetongue viruses: promise, progress, and perspectives. Front Microbiol. 2011; 2: 46[PubMed]
  • 2. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998; 17(12): 3351-62[PubMed]
  • 3. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006; 14(3): 361-70[PubMed]
  • 4. Holtz A. To build a killing machine. Scientist. 2007; 21(5): 48-55
  • 5. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 2006; 16(11): 879-86[PubMed]
  • 6. Norman KL, Lee PW. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today. 2005; 10(12): 847-55[PubMed]
  • 7. Alain T, Kim M, Johnston RN, Urbanski S, Kossakowska AE, Forsyth PA, et al. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br J Cancer. 2006; 95(8): 1020-7[PubMed]
  • 8. Cripe TP, Wang PY, Marcato P, Mahller YY, Lee PW. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther. 2009; 17(10): 1677-82[PubMed]
  • 9. Ou JHJ, Yen TSB. Human oncogenic viruses. 2010;
  • 10. Mohl BP, Roy P. Bluetongue virus capsid assembly and maturation. Viruses. 2014; 6(8): 3250-70[PubMed]
  • 11. Hu J, Dong CY, Li JK, Chen DE, Liang K, Liu J. Selective in vitro cytotoxic effect of human cancer cells by bluetongue virus-10. Acta Oncol. 2008; 47(1): 124-34[PubMed]
  • 12. Dong CY, Chen DE, Chen X, Cao ZH, Duan JR, Liu YH. Isolation of bluetongue virus strain HbC and its biological characters. Clin Med Res. 1998; : 180-2
  • 13. Liang K, Dong CY, Hu J, Zhang W, Chen J. The infectivity of bluetongue virus strain HbC_ (3) to MA782 cell. Virologica Sinica. 2005; 21(2): 153-6
  • 14. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000; 275(11): 7862-9[PubMed]
  • 15. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20(3): 157-98[PubMed]
  • 16. Ayiomamitis GD, Notas G, Zaravinos A, Drygiannakis I, Georgiadou M, Sfakianaki O, et al. Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity. Oncoscience. 2014; 1(6): 457-67[PubMed]
  • 17. DeMaula CD, Bonneau KR, MacLachlan NJ. Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies. Virus Res. 2000; 67(1): 59-66[PubMed]
  • 18. Boyce M, Roy P. Recovery of infectious bluetongue virus from RNA. J Virol. 2007; 81(5): 2179-86[PubMed]